Healthcare Industry News: Patent foramen ovale
News Release - October 17, 2007
Occlutech Obtains CE Mark for its "Figulla N" ASD and PFO OccludersJENA, Germany, October 17 (HSMN NewsFeed) -- Occlutech GmbH, the leading European developer and manufacturer of cardiac occlusion devices such as ASD, PFO and LAA occluders today announced that it has received CE mark approval for its range of ASD and PFO occluder under the Occlutech Figulla N brand.
The Occlutech ASD and PFO occluders are uniquely designed and individually braided, improving performance over existing technology. The fact that the occluders are not clamped gives them distinct advantages such as increased flexibility and a reduction of the amount of material implanted.
Occlutech's technology is protected by several patents and patents pending.
Starting in Germany, the products will be rolled out in Europe and in International markets over the next few months.
Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities, such as Atrial Septal Defects (ASD), or Patent foramen ovale (PFO), in a minimally invasive, non-surgical way. The market for these devices, and the PFO occluders in particular, are expected to expand significantly over the next few years.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.